The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Rhenium-186     rhenium

Synonyms: AC1L4OT7, 186Re, Rhenium, isotope of mass 186
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of rhenium


High impact information on rhenium


Chemical compound and disease context of rhenium


Anatomical context of rhenium

  • For rhenium-186 (both beta and gamma emitter), whole body scans and static images of joints and locoregional lymph nodes were performed [13].
  • Rhenium-186 leak is greater, as demonstrated by the higher blood activity and the measurable, although limited, dicentrics induction in blood lymphocytes [13].

Associations of rhenium with other chemical compounds


Analytical, diagnostic and therapeutic context of rhenium

  • In this perspective they focus on other therapeutic methods: endocavity treatment of cysts with rhenium-186, triconformational radiotherapy, radiosurgery, and widespread use of the trans-sphenoidal approach [15].


  1. Quantitative bone single-photon emission computed tomography for prediction of pain relief in metastatic bone disease treated with rhenium-186 etidronate. Israel, O., Keidar, Z., Rubinov, R., Iosilevski, G., Frenkel, A., Kuten, A., Betman, L., Kolodny, G.M., Yarnitsky, D., Front, D. J. Clin. Oncol. (2000) [Pubmed]
  2. Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Colnot, D.R., Ossenkoppele, G.J., Roos, J.C., Quak, J.J., de Bree, R., Börjesson, P.K., Huijgens, P.C., Snow, G.B., van Dongen, G.A. Clin. Cancer Res. (2002) [Pubmed]
  3. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. Breitz, H.B., Fisher, D.R., Wessels, B.W. J. Nucl. Med. (1998) [Pubmed]
  4. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. van Gog, F.B., Brakenhoff, R.H., Stigter-van Walsum, M., Snow, G.B., van Dongen, G.A. Int. J. Cancer (1998) [Pubmed]
  5. Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. Hamby, C.V., Chinol, M., Palestro, C.J., Manzo, C., Ferrone, S. Int. J. Cancer (1998) [Pubmed]
  6. Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibody. Breitz, H.B., Durham, J.S., Fisher, D.R., Weiden, P.L., DeNardo, G.L., Goodgold, H.M., Nelp, W.B. J. Nucl. Med. (1995) [Pubmed]
  7. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. Maxon, H.R., Schroder, L.E., Hertzberg, V.S., Thomas, S.R., Englaro, E.E., Samaratunga, R., Smith, H., Moulton, J.S., Williams, C.C., Ehrhardt, G.J. J. Nucl. Med. (1991) [Pubmed]
  8. High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. O'Sullivan, J.M., McCready, V.R., Flux, G., Norman, A.R., Buffa, F.M., Chittenden, S., Guy, M., Pomeroy, K., Cook, G., Gadd, J., Treleaven, J., Al-Deen, A., Horwich, A., Huddart, R.A., Dearnaley, D.P. Br. J. Cancer (2002) [Pubmed]
  9. Better results with rhenium-186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow-up randomized controlled multicentre study. Tebib, J.G., Manil, L.M., Mödder, G., Verrier, P., De Rycke, Y., Bonmartin, A., Devaux, J.Y., Chossat, F., Menkes, C.J., Kahan, A. Clinical and experimental rheumatology. (2004) [Pubmed]
  10. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. de Klerk, J.M., van Dijk, A., van het Schip, A.D., Zonnenberg, B.A., van Rijk, P.P. J. Nucl. Med. (1992) [Pubmed]
  11. Rhenium-186 HEDP as a boost to external beam irradiation in osteosarcoma. Sawyer, E.J., Cassoni, A.M., Waddington, W., Bomanji, J.B., Briggs, T.W. The British journal of radiology. (1999) [Pubmed]
  12. Systemic radionuclide therapy of bone metastases with strontium-89. Porter, A.T., Davis, L.P. Oncology (Williston Park, N.Y.) (1994) [Pubmed]
  13. Physical and biological dosimetry in patients undergoing radiosynoviorthesis with erbium-169 and rhenium-186. Manil, L., Voisin, P., Aubert, B., Guerreau, D., Verrier, P., Lebègue, L., Wargnies, J.P., Di Paola, M., Barbier, Y., Chossat, F., Menkes, C.J., Tébib, J., Devaux, J.Y., Kahan, A. Nuclear medicine communications. (2001) [Pubmed]
  14. Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use. Prakash, S., Went, M.J., Blower, P.J. Nucl. Med. Biol. (1996) [Pubmed]
  15. Individualized treatment of craniopharyngioma in children: ways and means. Marchal, J.C., Klein, O., Thouvenot, P., Bernier, V., Moret, C., Chastagner, P. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. (2005) [Pubmed]
WikiGenes - Universities